In 2017, ‘‘CCHT’’ invested Sh銀子anghai Ruizhou Biot聽路ech Co., Ltd. (hereinafter referred to見討 as ‘‘Shanghai Ruizhou’’, which is 秒影mainly targeted at the rese高得arch & developmen火得t of 20-valent pneumococ拍書cal polysaccharide conjugate vaccine湖微 project.

The 20-valent pneumococc著東al polysaccharid人下e conjugate vaccine has the most adv校話anced technology in the world. It is a綠懂n alternative product of Pfizer’話光s 13-valent pneumococcal conjugate va友多ccine and its specific們區ity is targeted at the Chines唱快e population. Therefore, i去下t has stronger protection, 個我higher protection coverage, more 如還advanced technolog刀拿y and huge market藍道 potential.

Dr. ZHU Xianchao, the technolog村服y leader, graduated from University 書森of California in the United States. He 新空has been engaged in the deve物自lopment of new-type vacci喝藍nes for more than 10 years as a sen友文ior scientist. Later on, he w爸做orked in the Research &熱農amp; Development Ce也雨nter of Greater China of Uni分微ted States Pharmacopoeial Conventio民車n. He has rich experience in pro都明duct development.